Fibroblast growth factor receptors, developmental corruption and malignant disease

Carcinogenesis

Volumn 34, Issue 10, 2013, Pages 2198-2205

  Kelleher, Fergal C ^a,b   O'Sullivan, Hazel ^b   Smyth, Elizabeth ^c   McDermott, Ray ^b   Viterbo, Antonella ^b,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 4547; BRIVANIB; DIURETIC AGENT; DOCETAXEL; DOVITINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 19 ANTIBODY; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; IMMUNOGLOBULIN; LY 2874455; MONOCLONAL ANTIBODY; NINTEDANIB; NVP BGJ 398; PACLITAXEL; PALIFERMIN; PAZOPANIB; PEMETREXED; PHOSPHATE BINDING AGENT; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; ROGERAFINIB; SORAFENIB; UNCLASSIFIED DRUG;

ACROCEPHALOSYNDACTYLY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BLADDER CANCER; BREAST CANCER; CALCIFICATION; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 10Q; CHROMOSOME 3Q; CHROMOSOME 4P; CHROMOSOME 5Q; CRANIOFACIAL SYNOSTOSIS; DEVELOPMENTAL DISORDER; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FATIGUE; GENE AMPLIFICATION; GERM LINE; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYDROPHOBICITY; HYPERPHOSPHATEMIA; HYPERTENSION; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN DOMAIN; RECEPTOR GENE; REVIEW; RHABDOMYOSARCOMA; SEMINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SPERMATOGENESIS; STOMACH CANCER; STOMACH CARCINOMA; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 84885136779     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt254     Document Type: Review

References (91)

1. Fu, L. et al. (2004) Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology, 145, 2594-2603.
2. Kharitonenkov, A., et al. (2005) FGF-21 as a novel metabolic regulator. J. Clin. Invest., 115, 1627-1635.
3. Razzaque, M.S., et al. (2007) The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J. Endocrinol., 194, 1-10.
4. Tomlinson, E., et al. (2002) Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology, 143, 1741-1747.
5. Beenken, A., et al. (2009) The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov., 8, 235-253.
6. Ornitz, D.M., et al. (2001) Fibroblast growth factors. Genome Biol., 2, 3005.
7. Turner, N., et al. (2010) Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer, 10, 116-129.
8. Jaye, M., et al. (1992) Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim. Biophys. Acta, 1135, 185-199.
9. Ong, S.H., et al. (2000) FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol. Cell. Biol., 20, 979-989.
10. Kouhara, H., et al. (1997) A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell, 89, 693-702.
11. Eswarakumar, V.P., et al. (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev., 16, 139-149.
12. Boilly, B., et al. (2000) FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev., 11, 295-302.
13. Robertson, S.C., et al. (2000) RTK mutations and human syndromes when good receptors turn bad. Trends Genet., 16, 265-271.
14. Ornitz, D.M., et al. (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev., 16, 1446-1465.
15. Greulich, H., et al. (2011) Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol. Med., 17, 283-292.
16. Zhang, X., et al. (2006) Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem., 281, 15694-15700.
17. De Moerlooze, L., et al. (2000) An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development, 127, 483-492.
18. Katoh, M., et al. (2007) WNT signaling pathway and stem cell signaling network. Clin. Cancer Res., 13, 4042-4045.
19. Katoh, M. (2008) WNT signaling in stem cell biology and regenerative medicine. Curr. Drug Targets, 9, 565-570.
20. Guagnano, V., et al. (2012) FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov., 2, 1118-1133.
21. Eswarakumar, V.P., et al. (2004) A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc. Natl Acad. Sci. USA, 101, 12555-12560.
22. Tanimoto, Y., et al. (2004) A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J. Biol. Chem., 279, 45926-45934.
23. Ibrahimi, O.A., et al. (2001) Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc. Natl Acad. Sci. USA, 98, 7182-7187.
24. Goetz, R., et al. (2009) Crystal structure of a fibroblast growth factor homologous factor (FHF) defines a conserved surface on FHFs for binding and modulation of voltage-gated sodium channels. J. Biol. Chem., 284, 17883-17896.
25. Yu, K., et al. (2000) Loss of fibroblast growth factor receptor 2 ligandbinding specificity in Apert syndrome. Proc. Natl Acad. Sci. USA, 97, 14536-14541.
26. Gaudenz, K., et al. (1998) Analysis of patients with craniosynostosis syndromes for a pro246Arg mutation of FGFR4. Mol. Genet. Metab., 64, 76-79.
27. Webster, M.K., et al. (1997) FGFR activation in skeletal disorders: too much of a good thing. Trends Genet., 13, 178-182.
28. Tiemann-Boege, I., et al. (2002) The observed human sperm mutation frequency cannot explain the achondroplasia paternal age effect. Proc. Natl Acad. Sci. USA, 99, 14952-14957.
29. Goriely, A., et al. (2003) Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line. Science, 301, 643-646.
30. Crow, J.F. (2003) Development. There's something curious about paternalage effects. Science, 301, 606-607.
31. Goriely, A., et al. (2009) Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat. Genet., 41, 1247-1252.
32. Eble, J.N. (1994) Spermatocytic seminoma. Hum. Pathol., 25, 1035-1042.
33. Rajpert-De Meyts, E., et al. (2003) The immunohistochemical expression pattern of Chk2, p53, p19INK4d, MAGE-A4 and other selected antigens provides new evidence for the premeiotic origin of spermatocytic seminoma. Histopathology, 42, 217-226.
34. Tavormina, P.L., et al. (1995) Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet., 9, 321-328.
35. Lim, J., et al. (2012) Selfish spermatogonial selection: evidence from an immunohistochemical screen in testes of elderly men. PLoS One, 7, e42382.
36. Hernández, S., et al. (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol., 24, 3664-3671.
37. Kiemeney, L.A., et al. (2010) A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat. Genet., 42, 415-419.
38. van Rhijn, B.W., et al. (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol., 21, 1912-1921.
39. Singh, D., et al. (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science, 337, 1231-1235.
40. Logié, A., et al. (2005) Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum. Mol. Genet., 14, 1153-1160.
41. Cappellen, D., et al. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet., 23, 18-20.
42. van Rhijn, B.W., et al. (2002) Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur. J. Hum. Genet., 10, 819-824.
43. Pierson, D. (2003) Benign Epidermal Tumors and Proliferation. 1st edn. Mosby, London, UK.
44. Hafner, C., et al. (2007) FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Mod. Pathol., 20, 895-903.
45. Chesi, M., et al. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet., 16, 260-264.
46. Reiter, A., et al. (1998) Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood, 92, 1735-1742.
47. Pollock, P.M., et al. (2007) Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene, 26, 7158-7162.
48. Davies, H., et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res., 65, 7591-7595.
49. Jang, J.H., et al. (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res., 61, 3541-3543.
50. Hunter, D.J., et al. (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet., 39, 870-874.
51. Katoh, M. (2009) FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. J. Invest. Dermatol., 129, 1861-1867.
52. Easton, D.F., et al. SEARCH collaborators; kConFab; AOCS Management Group. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087-1093.
53. Antoniou, A.C., et al.; Kathleen Cuningham Consortium for Research into Familial Breast Cancer; OCGN; Swedish BRCA1 and BRCA2 study collaborators; DNA-HEBON collaborators; EMBRACE; GEMO; CIMBA. (2008) Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet., 82, 937-948.
54. Tozlu, S., et al. (2006) Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a largescale real-time reverse transcription-PCR approach. Endocr. Relat. Cancer, 13, 1109-1120.
55. Moffa, A.B., et al. (2007) Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J. Cell. Physiol., 210, 720-731.
56. Dutt, A., et al. (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl Acad. Sci. USA, 105, 8713-8717.
57. Deng, N., et al. (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and cooccurrence among distinct therapeutic targets. Gut, 61, 673-684.
58. Hattori, Y., et al. (1996) Immunohistochemical detection of K-sam protein in stomach cancer. Clin. Cancer Res., 2, 1373-1381.
59. Hara, T., et al. (1998) Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab. Invest., 78, 1143-1153.
60. Oldridge, M., et al. (1995) Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome. Hum. Mol. Genet., 4, 1077-1082.
61. Weiss, J., et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl Med., 2, 62ra93.
62. Hammerman, P.S., et al. (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov., 1, 78-89.
63. An, S.J., et al. (2012) Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One, 7, e40109.
64. Paez, J.G., et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-1500.
65. Pao, W., et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA, 101, 13306-13311.
66. Lynch, T.J., et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 350, 2129-2139.
67. Kobayashi, S., et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 352, 786-792.
68. Engelman, J.A., et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-1043.
69. Guix, M., et al. (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest., 118, 2609-2619.
70. Ware, K.E., et al. (2010) Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One, 5, e14117.
71. Wang, J., et al. (2004) The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin. Cancer Res., 10(18 Pt 1), 6169-6178.
72. Streit, S., et al. (2004) Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int. J. Cancer, 111, 213-217.
73. Yamanaka, Y., et al. (1993) Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res., 53, 5289-5296.
74. Dieci, M.V., et al. (2013) Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov., 3, 264-279.
75. Kumar, S.B., et al. (2013) Fibroblast growth factor receptor inhibitors. Curr. Pharm. Des., 19, 687-701.
76. Zhao, Q., et al.; Kenna Shaw for TCGA research network. (2013) Tumorspecific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin. Cancer Res., 19, 2460-2472.
77. Spielberger, R., et al. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med., 351, 2590-2598.
78. Elbauomy Elsheikh, S., et al. (2007) FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res., 9, R23.
79. Fabrice Andre, TDB., et al. (2011) A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. Presented at 2011 ASCO Annual Meeting, Chicago, IL.
80. Pai, R., et al. (2008) Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res., 68, 5086-5095.
81. Desnoyers, L.R., et al. (2008) Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene, 27, 85-97.
82. Zhao, G., et al. (2011) A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol. Cancer Ther., 10, 2200-2210.
83. Marathe, P.H., et al. (2009) Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother. Pharmacol., 65, 55-66.
84. Huynh, H., et al. (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res., 14, 6146-6153.
85. Park, J.W., et al. (2011) Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res., 17, 1973-1983.
86. Finn, R.S., et al. (2012) Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res., 18, 2090-2098.
87. Llovet, J.M., et al. SHARP Investigators Study Group. (2008) Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 359, 378-390.
88. Hilberg, F., et al. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res., 68, 4774-4782.
89. Ellis, P.M., et al. (2010) Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin. Cancer Res., 16, 2881-2889.
90. Hanna, N., et al. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol., 22, 1589-1597.
91. Mross, K., et al. (2012) A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin. Cancer Res., 18, 2658-2667.